12:00 AM
Apr 03, 2000
 |  BC Week In Review  |  Company News  |  Sales & Marketing

Bio-Technology General, Al-Kindi Pharmaceutical Industries, Teva sales and marketing update

BTGC and TEVA amended a 1999 agreement under which TEVA will begin marketing BTGC' s recombinant human growth hormone (hGH) in the U.S. on July 1, 2000, rather than July 2003 (see BioCentury, Oct. 4, 1999). BTGC's hGH...

Read the full 166 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >